The future of digital healthcare
Building on the huge progress the NHS made during 2020, Gianpiero Celino, Clinical Director, Cegedim Healthcare Solutions, outlines a vision for the future of...
AstraZeneca releases updated US trial data on COVID-19 vaccine
AstraZeneca has released updated information about its COVID-19 vaccine following concern expressed by the Data and Safety Monitoring Board (DSMB) about initial data from...
MSD’s pembrolizumab added to NHSE COVID interim treatment list
MSD has reached an agreement with NHS England to make pembrolizumab available in England for eligible patients with metastatic MSI-H/dMMR colorectal cancer as an...
What does it really take to conduct a vaccine trial at scale?
The Pfizer/BioNTech COVID-19 vaccine trial was one of the largest and fastest clinical trials ever conducted. ICON, a global provider of outsourced drug and...
Medicago and GSK start Phase III trial of plant-derived COVID-19 vaccine
Medicago and GlaxoSmithKline (GSK) have started Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part...
MHRA responds to Oxford/AstraZeneca COVID-19 vaccine suspensions
Over the weekend, Ireland’s health ministry the National Immunisation Advisory Committee (NIAC) recommended temporary suspensions of the administration of the COVID-19 Oxford/AstraZeneca vaccine in...
COVID-19 and the impact on heart failure care
As the coronavirus pandemic continues to strain healthcare services in the UK, findings from the first patient survey into the impact of COVID-19 on...
Positive results for Vir Biotechnology and GSK’s monotherapy treatment of adults with COVID-19
Vir Biotechnology and GlaxoSmithKline (GSK) have announced evidence of profound efficacy from a trial evaluating VIR-7831 as monotherapy for the early treatment of COVID-19...
Positive opinion from CHMP for Lilly’s COVID-19 antibodies
Eli Lilly have announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion...
COVID-19 and key changes one year on
One year on from the first confirmed case of COVID-19 in the UK, Oli Hudson, Content Director at Wilmington Healthcare, takes a look at...
Latest articles
Antibiotic Research UK launches small research grants programme
Antibiotic Research UK (ANTRUK), the world’s first charity tackling bacterial antibiotic resistance, has just launched its largest grants programme to date, the 2021 Small...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
The first self-administered B-cell therapy for patients with relapsing forms of MS
Novartis receives European and UK licence for Kesimpta®▼(ofatumumab) Ofatumumab is a self-administered targeted B-cell depleting treatment option for adult patients living with relapsing forms of...
New COVID-19 test reduces testing time from 30 minutes to five
University of Birmingham researchers have invented a COVID-19 test that reduces testing time from 30 minutes to under five, whilst still delivering accurate results. The...
First AI-designed Immuno-Oncology drug to enter clinical trials
Discovered within 8 months of project initiation, the first AI-designed molecule for Immuno-Oncology is to enter human clinical trials. The A2a receptor antagonist, which is in development...